Type 1 Choroidal Neovascularization Evolution by Optical Coherence Tomography Angiography: Long-Term Follow-Up

Table 1

Patient demographic characteristics, baseline and final visual acuity, anti-VEGF therapy details, and follow-up interval.

Case	Age	Gender	Eye	Baseline BCVA (ETDRS)	Final BCVA (ETDRS)	Total no. of injections	Anti-VEGF agent	Follow-up (months)	CNV evolution	CNV growth pattern
1	77	F	RE	45	15	27	A	45	Atrophy	Symmetric
2	77	F	LE	30	45	28	A	36	Chronicity	Asymmetric
3	76	F	LE	35	40	29	A	58	Chronicity	Symmetric
4	78	M	RE	48	48	25	A	34	Chronicity	Asymmetric
5	78	M	LE	35	35	24	R	38	Fibrosis	Finger-like projections
6	41	F	LE	55	53	22	A	31	Chronicity	Asymmetric
7	90	F	LE	20	20	4	A	32	Stabilized	Asymmetric
8	54	F	LE	45	53	20	R	55	Chronicity	Symmetric
9	73	F	LE	40	35	14	R	40	Stabilized	Finger-like projections
10	75	F	RE	30	35	8	A	56	Stabilized	Symmetric
11	93	F	LE	48	50	7	A	38	Stabilized	Asymmetric
12	67	F	RE	50	55	3	R	36	Stabilized	Asymmetric
13	67	F	LE	20	40	8	R	36	Chronicity	Finger-like projections
14	60	M	RE	50	48	4	R	33	Stabilized	Asymmetric
15	75	M	RE	35	20	5	A	37	Stabilized	Symmetric
16	68	M	LE	55	35	12	A	54	Fibrosis	Asymmetric
17	74	F	RE	40	5	7	A	31	Atrophy	Inside fibrous capsule
18	85	M	RE	40	5	5	A	37	Atrophy	Asymmetric
19	75	F	RE	45	50	22	A	50	Chronicity	Asymmetric
20	76	F	LE	35	40	19	R	46	Chronicity	Inside fibrous capsule
21	94	F	RE	20	1	8	R	35	Hemorrage	Symmetric
22	75	M	RE	1	1	11	A	37	Atrophy	Asymmetric
23	75	M	LE	1	1	12	A	39	Atrophy	Asymmetric
24	83	F	RE	35	30	14	R	33	Chronicity	Symmetric
25	83	F	LE	35	20	11	R	33	Stabilized	Inside fibrous capsule
26	84	F	RE	45	30	12	R	33	Atrophy	Symmetric
27	87	F	RE	35	5	14	R	40	Fibrosis	Symmetric
28	87	F	LE	3	3	6	R	40	RPE tears	Finger-like projections
29	79	F	RE	50	45	9	R	38	Chronicity	Asymmetric
30	46	F	LE	20	45	11	A	46	Chronicity	Inside fibrous capsule
31	91	M	LE	20	2	14	A	32	Fibrosis	Symmetric
32	81	F	RE	5	1	13	A	33	Fibrosis	Symmetric
33	81	F	LE	50	50	14	R	33	Chronicity	Asymmetric
34	90	F	LE	5	20	12	A	39	Chronicity	Asymmetric
35	80	F	LE	48	50	14	R	58	Stabilized	Symmetric
36	72	F	LE	35	2	5	A	39	Hemorrage	Finger-like projections
37	88	M	RE	35	45	12	R	40	Chronicity	Asymmetric
38	77	F	RE	50	50	11	A	35	Chronicity	Asymmetric
39	86	F	LE	40	5	14	A	46	Fibrosis	Asymmetric
40	88	M	RE	1	1	6	A	33	Fibrosis	Asymmetric
41	95	M	LE	35	30	13	R	42	RPE tears	Symmetric
42	68	M	LE	53	53	9	R	39	Chronicity	Asymmetric
43	92	F	RE	20	5	9	R	32	Atrophy	Asymmetric
44	95	M	RE	48	30	12	A	37	Atrophy	Asymmetric
45	73	M	LE	45	45	7	A	38	Chronicity	Asymmetric
46	94	F	LE	1	1	9	R	39	Atrophy	Asymmetric
47	75	F	RE	30	30	5	R	39	Stabilized	Asymmetric
48	75	M	LE	35	20	7	A	31	Atrophy	Symmetric
49	87	F	LE	30	30	8	R	34	Chronicity	Asymmetric
50	54	F	RE	50	45	5	R	34	Fibrosis	Symmetric
51	54	F	LE	35	2	5	R	34	Fibrosis	Symmetric

RE: right eye; LE: left eye; A: aflibercept; R: ranibizumab; BCVA: best-corrected visual acuity; F: female; M: male.